CGNX COGNEX CORP Insider Trading

VP Darren Marc Long sold 20,252 shares (83.5% reduction) at $66.32–$66.52 for $1.3M while retaining 3,990 non-derivative shares and 194,617 in derivative holdings.

Darren Marc Long, Vice President at Cognex, executed four separate sales on 2026-05-27, totaling 20,252 shares for $1,343,456.61 at a blended average price of $66.34. This sale reduced his non-derivative holdings from 24,242 shares to 3,990 shares, representing an 83.5% reduction. However, the insider retains substantial derivative exposure: 16 ownership vehicles (Non-Qualified Stock Options and Restricted Stock Units) representing 194,617 total shares in contingent form, indicating this is a partial reduction of liquid equity rather than an exit of overall economic interest. The current stock price of $66.01 is -8.2% from its 52-week high of $71.90, and the stock has appreciated 22.8% over the past 30 days and 21.3% over the past 90 days, placing this sale in a period of recent strength. With a P/E of 97.07 and net income of $51,704,000.00 on revenue of $268,437,000.00, the company carries a elevated valuation multiple; the sale warrants monitoring as a data point on insider asset allocation decisions at current price levels.

CLO Fennell exercises stock options and sells significant position, disposing of more shares than acquired; first Form 4 activity for this insider.

Mark Fennell, Chief Legal Officer and Secretary of Cognex, exercised stock options to acquire over 60,000 shares on a single trading day and simultaneously sold nearly 65,000 shares at the same elevated price, resulting in a modest net reduction of holdings. The exercises covered a wide range of strike prices spanning from the low thirties to the mid-fifties, all executed and liquidated at the current trading price, which stands at the top of the company's 52-week range after a sharp rally over the preceding months. This is Fennell's first open-market activity recorded in the Form 4 system within the three-year window, suggesting either a new position or a first-time filing event rather than an established pattern. The structure—exercising vested options and immediately selling—is a common tax and liquidity management approach for officers, though the scale of the transaction and the pristine timing at the cycle high warrants attention as part of broader insider positioning in a profitable company trading at a stretched valuation multiple.

VP exercised stock options and immediately sold all shares on same days, resulting in modest net reduction in holdings.

Laura Ann Macdonald, VP and PAO at Cognex, exercised roughly 137,500 shares across nine transactions between May 11–12, immediately selling approximately 139,700 shares on the same or next day, netting a small reduction in holdings. This pattern—exercise followed by same-day sale at a meaningfully higher price—is typical of tax-efficient option monetization rather than a statement about conviction in the stock. The stock is trading near its 52-week high after a sharp rally over the past three months, and Macdonald's sales occurred at prices well above the exercise prices, capturing most of the intrinsic value without holding overnight. Her filing history shows ten open-market sales in the past three years and no open-market purchases, consistent with a pattern of exercising stock compensation and liquidating for proceeds rather than accumulating. For a profitable company with growing revenue, this looks like routine compensation realization by a named officer—the type of mechanical sell-to-exercise that occurs across thousands of filers each year—rather than meaningful insider sentiment about the stock's near-term direction.

Director Dianne M Parrotte sold 44,000 shares of CGNX at $54.00 for $2.4M on 2026-03-02, reducing holdings by 56.8%.

Dianne M Parrotte executed four separate sales totaling 44,000 shares for $2,376,000.00 at $54.00 per share on 2026-03-02, reducing her stake from 77,431 shares to 33,431 shares—a reduction of 56.8% of her pre-transaction holdings. The blended transaction price of $54.00 is 0.73% above the current price of $53.61 and sits 8.8% below the 52-week high of $58.79, placing the sale within the upper portion of the stock's recent trading range despite a strong 30-day (+38.4%) and 90-day (+42.2%) price run-up. Her cross-ticker track record shows 1 prior buy with an average 90-day return of +3.2% and a 100% win rate, though that specific trade at CGNX on 2024-08-07 followed a pattern where the stock rose after her buy. This large, multi-tranche liquidation represents a material reduction in director-level ownership and warrants monitoring of subsequent filings to assess whether it reflects a one-time capital event or a broader shift in her conviction in the company.

Head of Corporate M&A Kuechen Joerg sells 61.9K shares (91.1% of holdings) for $3.5M at avg $56.03

Kuechen Joerg, Head of Corporate M&A at Cognex, executed 4 separate sales on 2026-02-20 totaling 61,900 shares for $3,468,385.92, reducing his holdings from 67,932 shares to 6,032 shares—a 91.1% reduction. The sales occurred at prices ranging from $55.98 to $56.24 (blended average $56.03), near the stock's 52-week high of $58.79. The timing is notable given the stock's recent 45.6% 30-day rally and 51.5% 90-day surge, suggesting the insider liquidated a substantial majority of his position after a significant price appreciation run. This magnitude of insider selling—particularly from an executive focused on mergers and acquisitions strategy—represents meaningful capital redeployment and warrants scrutiny into whether it reflects changed conviction around growth prospects or M&A pipeline visibility.

Director Willett Robert liquidates entire 177,052-share CGNX position for $10,337,198.73

Robert Willett, a Director at Cognex, executed 2 separate sales on 2026-02-12, liquidating his complete shareholding of 177,052 shares (177.1K shares) at a blended average price of $58.39, generating $10,337,198.73 ($10.3M) in proceeds. The sales occurred at $58.39 per share when the current stock price stands at $58.79, indicating the trades were executed just below the current market level. Notably, the stock has risen 46.8% over the prior 30 days and 59.9% over 90 days, and the transaction price represents 99.3% of the current 52-week high of $58.79. The complete elimination of his position—from 177,052 shares to 0 shares (−100.0% of pre-transaction holdings)—represents a full exit by a board member from a company with a market cap of $9.7B and a P/E ratio of 82.80.

Director Anthony Sun sells 26,000 CGNX shares (49.4% of holdings) at $40.03; stock trades $41.53 today, -21.5% from 52-week high.

Director Anthony Sun executed a substantial sale on 2024-11-22, disposing of 26,000 shares—reducing his holdings by 49.4%—at $40.03 per share for a total value of $1,040,670.80. The sale occurred while COGNEX trades below its 52-week range high of $52.91 by 21.5%, though the stock has posted 30-day and 90-day gains of 6.9% and 5.8% respectively, suggesting near-term price recovery. Against broader context, COGNEX reported annual revenue contraction of -16.8%, a historically elevated P/E of 79.87, and latest quarterly net income of $29,591,000.00 on revenue of $234,742,000.00—metrics consistent with a transition or challenging demand environment. The scale of the reduction (leaving 26,608 shares post-transaction) warrants tracking whether this reflects portfolio reallocation or a shift in the director's capital allocation posture.

CFO Dennis Fehr buys 6,570 shares at $38.04 avg; current price $38.89, 52-week high $52.91

Dennis Fehr, SVP and Chief Financial Officer, made 2 separate purchases totaling 6,570 shares for $249,919.50, establishing his first position at COGNEX. The stock is currently trading 26.5% below its 52-week high of $52.91, and the company faces significant headwinds including 16.8% annual revenue decline and an elevated P/E of 84.54, suggesting the market remains cautious despite near-term price recovery (+2.2% over 30 days). A CFO's initial equity stake acquisition during a period of operational contraction and valuation pressure presents a material signal, though the absence of prior CFO trading history at this ticker limits ability to contextualize the transaction against his established patterns.

Director Parrotte buys 2,000 shares of CGNX at $38.62; stock down -26.8% from 52-week high amid -16.8% annual revenue decline.

Director Dianne M Parrotte purchased 2,000 shares at $38.62, increasing her holdings from 9,340 to 11,340 shares. The purchase occurs in a context of material stock weakness: the current price of $38.75 is -26.8% from the 52-week high of $52.91, and the stock has declined -20.0% over the prior 30 days. Cognex's fundamentals show strain, with annual revenue down -16.8% year-over-year despite a market cap of $6.6B and a notably elevated P/E of 84.24, suggesting elevated valuation relative to current earnings. This is a discretionary open-market purchase by a director during a period of significant stock decline and deteriorating top-line growth.